Evidence map›Paper›PMID 24595654›Full record

Trial reportDigestive diseases and sciences2014

Nickel free-diet enhances the Helicobacter pylori eradication rate: a pilot study.

M Campanale, E Nucera, V Ojetti, V Cesario, T A Di Rienzo, G D'Angelo, S Pecere, F Barbaro, G Gigante, T De Pasquale and 5 more

Registry-linked trialAbstract readComparative StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Digestive diseases and sciences, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06529913 (Model of diseAses Related to Environmental Exposure to Heavy meTals, nanopaRticles and Emergent Contaminants, Using a dIgital platfOrm of Clinical and Bio-humoral Data), which is not on this map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.2field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06529913 narecruitingnot on this mapstarted 2025, after this paper: background citation

Model of diseAses Related to Environmental Exposure to Heavy meTals, nanopaRticles and Emergent Contaminants, Using a dIgital platfOrm of Clinical and Bio-humoral Data: the Way to Susceptibility/RisK BiomArker [MATRIOSKA Study] - The Seed.

TypeinterventionalSponsorFondazione Policlinico Universitario Agostino Gemelli IRCCSRan2025 to 2026Enrolled280ConditionsAllergic Contact Dermatitis, Metal Allergy, Food Allergy, Nickel SensitivityArmsCollection of environmental, biological, and clinical data
3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 33 citations in OpenAlex.

  1. Trial
  2. Challenges and Prospects for Eradication ofPathogens (Basel, Switzerland) · 2025
    Review
  3. Review
  4. The Effects of Vitamins and Micronutrients onJournal of immunology research · 2022
    Review
  5. The effect of a low-nickel diet and nickel sensitization on gastroesophageal reflux disease: A pilot study.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2021
    Article
  6. Review
  7. Structure and dynamics of Helicobacter pylori nickel-chaperone HypA: an integrated approach using NMR spectroscopy, functional assays and computational tools.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2018
    Article
  8. Management of multi-drug resistantGastroenterology and hepatology from bed to bench · 2017
    Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

M CampanaleInternal Medicine and Endoscopy, Gemelli Hospital, Largo A. Gemelli, 8, 00168, Rome, Italy, chiaracampanale@hotmail.com.
E Nucera
V Ojetti
V Cesario
T A Di Rienzo
G D'Angelo
S Pecere
F Barbaro
G Gigante
T De Pasquale
A Rizzi
G Cammarota
D Schiavino
F Franceschi
A Gasbarrini
Agostino Gemelli University Polyclinic · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe Helicobacter pylori eradication rate with standard triple therapy is very low. H. pylori is known to require the nickel-containing metalloenzymes urease and NiFe-hydrogenase to survive at the low pH environment in the stomach.

aimTo compare the H. pylori eradication rate of a nickel free-diet associated with standard triple therapy and standard triple therapy alone as the first-line regimen.

methodsFifty-two sex- and age-matched patients at the first diagnosis of H. pylori infection were randomized 1:1 into two different therapeutic schemes: (1) standard LCA (26 patients): lansoprazole 15 mg bid, clarithromycin 500 mg bid and amoxicillin 1,000 mg bid for 7 days with a common diet; (2) standard LCA plus a nickel free-diet (NFD-LCA) (26 patients). Patients followed 30 days of a nickel-free diet plus a week of lansoprazole 15 mg bid, clarithromycin 500 mg bid and amoxicillin 1,000 mg bid starting from day 15 of the diet.

resultsAll patients completed the study. A significantly higher eradication rate was observed in the NFD-LCA group (22/26) versus LCA group (12/26) (p < 0.01). Only a few patients (9 of 52) reported the occurrence of mild therapy-related side effects, without any significant differences between the two groups.

conclusionsThe addition of a nickel-free diet to standard triple therapy significantly increases the H. pylori eradication rate. The reduction of H. pylori urease activity due to the nickel-free diet could expose the bacterium to gastric acid and increase H. pylori's susceptibility to amoxicillin. Further studies are necessary to confirm this preliminary result.

Indexed as

Helicobacter pyloriNickelAdultAmoxicillinAnti-Bacterial AgentsAnti-Ulcer AgentsClarithromycinContraindicationsDrug Therapy, CombinationFemaleHelicobacter InfectionsHumansLansoprazoleMalePilot ProjectsAmoxicillinAnti-Bacterial AgentsAnti-Ulcer AgentsClarithromycinLansoprazoleNickel

Identifiers

PMID24595654
OpenAlexW1983580397

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.